Immunity war: A novel therapy for lymphoma using T-cell bispecific antibodies

Ajay Prakash; Catherine S. Diefenbach

doi:10.1158/1078-0432.CCR-18-1363

Immunity war: A novel therapy for lymphoma using T-cell bispecific antibodies

Ajay Prakash, Catherine S. Diefenbach

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

The activity of T-cell-mediated immunotherapies in B-cell lymphoma has been limited to date. The novel bispecific antibody CD20-TCB has a 2:1 antibody design to maximize T-cell engagement and demonstrates activity in preclinical models. This may represent a novel therapeutic approach for patients with relapsed/refractory non-Hodgkin lymphoma (NHL).

Original language	English (US)
Pages (from-to)	46314632
Number of pages	1
Journal	Clinical Cancer Research
Volume	24
Issue number	19
DOIs	https://doi.org/10.1158/1078-0432.CCR-18-1363
State	Published - Oct 1 2018
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2018 American Association for Cancer Research.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1158/1078-0432.CCR-18-1363

Find It

Find It at U of M Libraries

Cite this

@article{047a02bcaadb4974bc402d208beea4db,

title = "Immunity war: A novel therapy for lymphoma using T-cell bispecific antibodies",

abstract = "The activity of T-cell-mediated immunotherapies in B-cell lymphoma has been limited to date. The novel bispecific antibody CD20-TCB has a 2:1 antibody design to maximize T-cell engagement and demonstrates activity in preclinical models. This may represent a novel therapeutic approach for patients with relapsed/refractory non-Hodgkin lymphoma (NHL).",

author = "Ajay Prakash and Diefenbach, {Catherine S.}",

note = "Publisher Copyright: {\textcopyright} 2018 American Association for Cancer Research.",

year = "2018",

month = oct,

day = "1",

doi = "10.1158/1078-0432.CCR-18-1363",

language = "English (US)",

volume = "24",

pages = "46314632",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "19",

}

TY - JOUR

T1 - Immunity war

T2 - A novel therapy for lymphoma using T-cell bispecific antibodies

AU - Prakash, Ajay

AU - Diefenbach, Catherine S.

PY - 2018/10/1

Y1 - 2018/10/1

N2 - The activity of T-cell-mediated immunotherapies in B-cell lymphoma has been limited to date. The novel bispecific antibody CD20-TCB has a 2:1 antibody design to maximize T-cell engagement and demonstrates activity in preclinical models. This may represent a novel therapeutic approach for patients with relapsed/refractory non-Hodgkin lymphoma (NHL).

AB - The activity of T-cell-mediated immunotherapies in B-cell lymphoma has been limited to date. The novel bispecific antibody CD20-TCB has a 2:1 antibody design to maximize T-cell engagement and demonstrates activity in preclinical models. This may represent a novel therapeutic approach for patients with relapsed/refractory non-Hodgkin lymphoma (NHL).

UR - http://www.scopus.com/inward/record.url?scp=85054094196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054094196&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-18-1363

DO - 10.1158/1078-0432.CCR-18-1363

M3 - Article

C2 - 29884742

AN - SCOPUS:85054094196

SN - 1078-0432

VL - 24

SP - 46314632

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 19

ER -

Immunity war: A novel therapy for lymphoma using T-cell bispecific antibodies

Abstract

Bibliographical note

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this